Lithium has accumulated substantial evidence for neuroprotective effects beyond its primary use in bipolar disorder. Observational studies in regions with naturally occurring lithium in drinking water show inverse associations with dementia incidence and suicide rates. Lithium augmentation studies in TRD show suicide-reduction benefit beyond depression treatment. Mechanistically, lithium inhibits GSK-3, elevates BDNF, reduces tau phosphorylation, and has anti-inflammatory effects relevant to dementia biology. The longevity-psychiatry frame engages low-dose lithium as a potential cognitive-protective intervention with established safety profile when monitored.
The mechanistic case is substantial. Lithium inhibits glycogen synthase kinase-3 (GSK-3), a kinase involved in tau phosphorylation and many cellular processes relevant to neurodegeneration. Lithium elevates BDNF expression, supporting synaptic plasticity. Lithium has direct anti-inflammatory effects. Lithium supports adult neurogenesis. The mechanisms overlap substantially with the targets of pharmaceutical development for Alzheimer's disease and other neurodegenerative conditions; lithium is the existing drug that engages multiple of these targets simultaneously.
The clinical evidence is suggestive but not yet definitive. Population studies in Texas, Denmark, and elsewhere have shown inverse associations between drinking-water lithium levels and dementia and suicide. The Lithium-Plus-Antidepressant studies in TRD show consistent suicide-reduction benefit. The Forlenza low-dose lithium trial in MCI showed slowed cognitive decline at very low doses (150–300 mg/day). The dementia-prevention evidence is not yet at the level required for routine prescription specifically for cognitive protection, but the case is real and worth tracking as more evidence emerges.
The clinical use cases. Lithium augmentation in TRD remains the most evidence-based indication (Stage 10.3). Mood stabilization in bipolar disorder is the primary FDA indication. Suicide-reduction benefit in patients with prior suicide attempts or chronic ideation supports use. Low-dose lithium for cognitive protection in selected patients with elevated dementia risk — particularly those with mood disorders that benefit from lithium for mood reasons anyway — has emerging rationale. The off-label use specifically for cognitive protection in patients without psychiatric indication is not yet supported by adequate evidence.
The monitoring requirements are non-negotiable. Baseline: serum creatinine, TSH, calcium, electrolytes, urinalysis, ECG in older patients, weight. Therapeutic monitoring: lithium level at 5–7 days after dose change and steady state, then every 3–6 months stable. Annual: renal function, thyroid function, calcium. The narrow therapeutic index and progressive renal and thyroid effects require ongoing attention. The dose for TRD augmentation typically targets levels of 0.4–0.8 mEq/L (lower than the bipolar range); the dose for cognitive protection in research has been even lower (150–300 mg/day with subtherapeutic levels). The discipline is to use lithium where the evidence supports it, monitor consistently across the long course of treatment, and engage with the emerging neuroprotection evidence thoughtfully — neither prescribing widely off-label nor dismissing the data as it accumulates.